< Back to previous page
Researcher
Chris Marine
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Marine Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From1 Oct 2013 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2009 → 31 Dec 2016
Projects
21 - 30 of 62
- Metastatic plasticity in melanomaFrom1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- Circulating tumor cells in metastatic melanoma.From1 Oct 2019 → 30 Sep 2020Funding: Foundations, funds and other with scientific goal
- Preventing therapy-induced cancer stemnessFrom1 Oct 2019 → TodayFunding: IOF - technology concept exploration, BOF - projects
- Non-genetic plasticity as driver of melanoma intra-tumor heterogeneity and metastatic disseminationFrom1 Oct 2019 → 1 Oct 2021Funding: FWO fellowships
- Preventing therapy-induced stemness as a salvage strategy to precision oncologyFrom1 Jan 2019 → 31 Dec 2022Funding: Foundations, funds and other with scientific goal
- Characterisation of the melanocyte lineage in mice and humans to find specific melanocytic biomarkersFrom3 Sep 2018 → 14 Mar 2024Funding: FWO Strategic Basic Research Grant, Foundations, funds and other with scientific goal
- Treating melanoma as an infectious diseaseFrom1 Sep 2018 → 31 Aug 2022Funding: Foundations, funds and other with scientific goal
- Mass cytometry by time-of-flight: next-generation flow cytometry for multiplexed single cell analysisFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Single-cell omics in high throughput and at spatial resolutionFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Identification and characterisation of drug-tolerant state(s) induced by MAPK-inhibitionFrom1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 158
- Cell States in Cancer: Drivers, Passengers, and Trailers.(2024)
Authors: Chris Marine
Pages: 610 - 614 - A tailored mouse model for dissecting the earliest phases of melanoma dissemination(2024)
Authors: Nina Van Raemdonck, Chris Marine
- Cancer Evolution: A Multifaceted Affair.(2024)
Authors: Chris Marine
Pages: 36 - 48 - A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma(2024)
Authors: Dennis Pedri, Ewout Landeloos, Yannick Van Herck, Katy Vandereyken, Thierry Voet, Wim Annaert, Diether Lambrechts, Veerle Boecxstaens, Joost van den Oord, Francesca Bosisio, et al.
- Deciphering melanoma transcriptional heterogeneity: TCF4 and the mesenchymal-like switch(2023)
Authors: Dennis Pedri, Wim Annaert, Chris Marine
- Tumor endothelial cell autophagy is a key vascular-immune checkpoint in melanoma(2023)
Authors: Francesca Rizzollo, Johan Van Weyenbergh, Oliver Bechter, Francesca Bosisio, Chris Marine, Diether Lambrechts, Gabriele Bergers, Patrizia Agostinis
- STmut: a framework for visualizing somatic alterations in spatial transcriptomics data of cancer(2023)
Authors: Chris Marine
- Perivascular niches: critical hubs in cancer evolution(2023)
Authors: Ada Nowosad, Chris Marine, Panagiotis Karras
Pages: 897 - 910 - Development of novel methods for single-cell whole-genome amplification to study cancer heterogeneity.(2023)
Authors: Koen Theunis, Thierry Voet, Chris Marine
- The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells (vol 21, pg 525, 2007)(2023)
Authors: Chris Marine
Pages: 861 - 861
Patents
1 - 10 of 10
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Direct and selective inhibition of mdm4 for treatment of cancer (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)